ZNF566 antisense RNA 1 (ZNF566-AS1)

ZNF566 antisense RNA 1 (ZNF566-AS1), also known as CTD-2630F21.1, is a long non-coding RNA (lncRNA) classified as an antisense RNA because it is transcribed from the DNA strand opposite to the ZNF566 gene locus[1]. ZNF566-AS1 does not code for a protein and is primarily linked to the regulation of gene expression, potentially impacting the expression of the adjacent ZNF566 gene or other targets through epigenetic, transcriptional, or RNA-mediated mechanisms[2]. Unlike classic drug targets such as receptors or enzymes, ZNF566-AS1 is not presently recognized as a therapeutic drug target, and there are no known drugs directed against it. While lncRNAs and, specifically, antisense lncRNAs are increasingly implicated as biomarkers and modulators in diverse disease states—including cancer and inherited diseases—the specific biological functions and clinical roles of ZNF566-AS1 remain largely uncharacterized. Diseases with genetic associations reported include retinitis pigmentosa[1], but direct pathogenic mechanisms or therapeutic implications have not been described. Note: This entry is likely to be incorrect or insufficient as a classic therapeutic target: ZNF566-AS1 is a non-coding RNA, not a protein, receptor, enzyme, or transporter; there are no approved agonists/antagonists, and its disease roles are unclear and not targetable with current therapeutics. Use caution with its inclusion in structured therapeutic target databases.

Other names

CTD-2630F21.1ZNF566-AS1